|
[1]Liver Doctor Editorial Department.The mortality of druginduced liver disease ranked at the fifth in the world[J].Liver Doctor,2006,(5):68-69.
|
|
[2]JIANG HJ.Clinical epidemiology of drug-induced liver injury:an analysis of 102 cases[J].Chin Hepatol,2013,18(12):823-824.(in Chinese)江红接.102例药物性肝损伤临床流行病学分析[J].肝脏,2013,18(12):823-824.
|
|
[3]CHEN M,SUZUKI A,BORLAK J,et al.Drug-induced liver injury:interactions between drug properties and host factors[J].JHepatol,2015,63(2):503-514.
|
|
[4]SHEN T,DUAN ZJ,ZHUANG H.Epidemiology of drug-induced liver injury[J].Chin Hepatol,2015,20(10):819-823.(in Chinese)沈弢,段昭君,庄辉.药物性肝损伤的流行病学[J].肝脏,2015,20(10):819-823.
|
|
[5]ZHOU Y,YANG L,LIAO Z,et al.Epidemiology of drug-induced liver injury in China:a systematic analysis of the Chinese literature including 21,789 patients[J].Eur J Gastroenterol Hepatol,2013,25(7):825-829.
|
|
[6]CHALASANI N,BONKOVSKY HL,FONTANA R,et al.Features and outcomes of 899 patients with drug-induced liver injury:the DILIN prospective study[J].Gastroenterology,2015,148(7):1340-1352.
|
|
[7]ZHAO H,CHENG C,XIE W.Pathogenesis of antituberculosis drugs induced liver injury[J/CD].Chin J Liver Dis:Electronic E-dition,2015,7(4):11-13.(in Chinese)赵红,程澄,谢雯.抗结核药物致肝损伤的发病机制[J/CD].中国肝脏病杂志:电子版,2015,7(4):11-13.
|
|
[8]GUO YX,DENG Y,LI C,et al.Mitochondria dysfunction is involved in the pathogenesis of isoniazid-induced hepatotoxicity[J].Chin J Clin Ther,2015,20(3):356-360.(in Chinese)郭瑶雪,邓晔,李春,等.异烟肼致线粒体损伤引起药物性肝损伤研究进展[J].中国临床药理学与治疗学,2015,20(3):356-360.
|
|
[9]SONG HB,HAN L.Epidemiologic characteristics,risk factors and safety evaluation of traditional Chinese medicine induced liver injury[J].Chin J Pharmacol Toxicity,2016,30(4):291-305.(in Chinese)宋海波,韩玲.中药肝损伤的流行特点、风险因素及评价[J].中国药理学与毒理学杂志,2016,30(4):291-305.
|
|
[10]SHEN Q,FENG YL,WANG YQ.Analysis of 596 cases of druginduced liver injury in elderly patients[J].Chin J Pharmacoepidemiol,2015,24(8):474-478,482.(in Chinese)沈芊,冯于洛,王育琴.596例老年患者药源性肝损害不良反应分析[J].药物流行病学杂志,2015,24(8):474-478,482.
|
|
[11]ZHANG CP,CUI XL,WANG YM.Retrospective analysis of 200patients with drug induced liver injury[J].Chin Hepatol,2014,19(7):483-486.(in Chinese)张长平,崔向丽,王咏梅.药物性肝损伤200例临床分析[J].肝脏,2014,19(7):483-486.
|
|
[12]WANG YE,YAO GB.Drug induced liver injury associated with Chinese herbal medicine and herbal related food supplements[J].Chin JDig,2007,27(7):435-438.(in Chinese)王月娥,姚光弼.中草药和相关保健食品引起药物性肝病的研究[J].中华消化杂志,2007,27(7):435-438.
|
|
[13]WANG XF,LIU YX.Drug-induced liver injury:clinical characteristics analysis of traditional Chinese medicine and western medicine induced liver injury[J].Chin Hepatol,2016,21(1):13-16.(in Chinese)王新发,刘映霞.中药与西药源性药物性肝损害的临床特点分析[J].肝脏,2016,21(1):13-16.
|
|
[14]Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志,2015,31(11):1752-1769.
|
|
[15]CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al.ACGClinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol,2014,109(7):950-966.
|
|
[16]REN ZQ,WANG JH,GUO XY,et al.A review analysis of Chinese literatures 2005-2014:clinical features of drug-induced liver injury[J].Chin J Pharmacoepidemiol,2016,25(5):284-289.(in Chinese)任张青,王进海,郭晓燕,等.2005~2014年我国药物性肝损伤临床综合分析[J].药物流行病学杂志,2016,25(5):284-289.
|
|
[17]ANDRADE RJ,LUCENA MI,ALONSO A,et al.HLA class IIgenotype influences the type of liver injury in drug-induced idiosyncratic liver disease[J].Hepatology,2004,39(6):1603-1612.
|
|
[18]CHEN SY,JIANG XQ,LIU TS,et al.Etiology and clinical manifestation of drug-induced liver disease[J].Chin J Hepatol,2000,8(4):244.(in Chinese)陈世耀,蒋晓渠,刘天舒,等.药物性肝病的病因和临床表现[J].中华肝脏病杂志,2000,8(4):244.
|
|
[19]HOLT MP,JU C.Mechanisms of drug-induced liver injury[J].AAPS J,2006,8(1):e48-e54.
|
|
[20]ZHANG HY,WU Y.Pathogenesis and prevention/treatment of drug-induced liver injury[J].J Clin Hepatol,2008,24(6):466-468.(in Chinese)张海云,吴扬.药物性肝损害的发病机制及防治[J].临床肝胆病杂志,2008,24(6):466-468.
|
|
[21]HU Q,LIU W,SHAO H.Research progress of pharmacotherapy drug-induced liver injury[J].Chin J Clin Pharmacol Ther,2016,21(2):231-236.(in Chinese)胡琴,刘维,邵宏.药物性肝损伤的药物治疗研究进展[J].中国临床药理学与治疗学,2016,21(2):231-236.
|
|
[22]DANAN G.Causality assessment of drug-induced liver injury[J].J Hepatol,1988,7(1):132-136.
|
|
[23]DANAN G,BENICHOU C.Causality assessment of adverse reactions to drugs-Ⅰ.A novel method based on the conclusions of international consensus meetings:application to drug-induced liver injuries[J].J Clin Epidemiol,1993,46(11):1323-1330.
|
|
[24]MARIA VA,VICTORINO RM.Development and validation of a clinical scale for the diagnosis of drug---induced hepatitis[J].Hepatology,1997,26(3):664-669.
|
|
[25]HUANG ZQ.Schiff's Diseases of the Liver[M].Beijing:Chemical Industry Press,2004:947-948.(in Chinese)黄志强.希夫肝脏病学[M].北京:化学工业出版社,2004:947-948.
|
|
[26]YAO GB,CHEN CW.Drug-induced and toxic liver disease[M].Shanghai:Shanghai Scientific&Technical Publishers,2002:88-89.(in Chinese)姚光弼,陈成伟.药物与中毒性肝病[M].上海:上海科学技术出版社,2002:88-89.
|
|
[27]LIU ZX,KAPLOWITZ N.Immune-mediated drug-induced liver disease[J].Clin Liver Dis,2002,6(3):755-774.
|
|
[28]BNICHOU C.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatol,1990,11(2):272-276.
|
|
[29]XU Q,LIU H,ZHANG YX.Causes of drug-induced liver injury:a retrospective study of 122 cases[J].World Chin J Dig,2016,24(20):3177-3181.(in Chinese)徐琴,刘浩,张跃新.药物性肝损伤患者的回顾性分析122例[J].世界华人消化杂志,2016,24(20):3177-3181.
|
|
[30]FISHER K,VUPPALANCHI R,SAXENA R.Drug-induced liver injury[J].Arch Pathol Lab Med,2015,139(7):876-887.
|
|
[31]ANDRADE RJ,ROBLES M,FERNNDEZ-CASTAER A,et al.Assessment of drug-induced hepatotoxicity in clinical practice:a challenge for gastroenterologists[J].World J Gastroenterol,2007,13(3):329-340.
|
|
[32]LEE WM,HYNAN LS,ROSSARO L,et al.Intravenous N-acetylcysteine improves transplant-free survival in early stage nonacetaminophen acute liver failure[J].Gastroenterology,2009,137(3):856-864.
|
|
[33]XIE YQ,LIANG XM,YE WX.Research advances in pharmacological action and clinical application of reduced glutathione[J].China Pharm,2013,22(7):124-127.(in Chinese)谢雅清,梁晓美,叶伟霞.还原型谷胱甘肽的药理作用与临床应用研究进展[J].中国药业,2013,22(7):124-127.
|
|
[34] MAO YM,ZENG MD,CHEN Y,et al.Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases:a randomized,double-blind,multi-doses,active drug controlled,multi-center study[J].Chin J Hepatol,2009,17(11):847-851.(in Chinese)毛益民,曾民德,陈勇,等.异甘草酸镁治疗ALT升高的慢性肝病的多中心、随机、双盲、多剂量、阳性药物平行对照临床研究[J].中华肝脏病杂志,2009,17(11):847-851.
|
|
[35]WREE A,DECHNE A,HERZER K,et al.Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury[J].Digestion,2011,84(1):54-59.
|
|
[36]RUSSO MW,GALANKO JA,SHRESTHA R,et al.Liver transplantation for acute liver failure from drug induced liver injury in the United States[J].Liver Transpl,2004,10(8):1018-1023.
|
DownLoad: